You hit your goal weight. Now what? Do you stay on 15 mg tirzepatide forever, or can you step down to a smaller weekly dose and hold the loss? This is the question almost nobody answered clearly when GLP-1s exploded — and the wrong answer costs you either money or your results.

Here's the honest version, grounded in the trials that actually studied it.

Quick Answer

Stopping fully regains most weight: ~2/3 back within a year (STEP-1)
No trial has proven a low "maintenance dose" holds loss as well as full dose
SURMOUNT-4: staying on tirzepatide kept ~90% of loss vs regain on placebo
Any dose change should be gradual and supervised by your prescriber

What "Maintenance Dose" Actually Means

The phrase gets thrown around loosely, so let's separate two very different things.

Continued full-dose treatment means you reach your goal weight and keep taking the dose that got you there — often the maximum tolerated dose (2.4 mg semaglutide, 10–15 mg tirzepatide). This is what the maintenance trials tested.

Dose reduction ("stepping down") means you deliberately move to a lower weekly dose after reaching goal, hoping the smaller amount is enough to prevent regain. This is what most patients want — fewer side effects, lower cost, less medication. It's also the version with almost no controlled trial evidence behind it.

That gap matters. When a clinic markets a "maintenance dose," they usually mean the second thing. The trials proved the first thing. Do not confuse the marketing with the evidence.

Obesity is now treated as a chronic condition, similar to hypertension or high cholesterol. You don't take a blood-pressure pill for six months, hit target, and quit. The drug manages the condition while you take it. GLP-1s appear to work the same way — the biology that drove your weight up doesn't disappear because the scale hit a number.

Medical Disclaimer: This article is for general education only and is not medical advice. It does not replace a consultation with a licensed clinician. Do not start, stop, or change the dose of any prescription medication based on this article. GLP-1 medications require a prescription and ongoing medical supervision. Always follow your own prescriber's instructions and the FDA-approved labeling for your specific medication.

What Happens If You Just Stop

This is the foundation for everything else, because it defines the problem a maintenance strategy is trying to solve.

The STEP-1 trial extension followed people after they stopped semaglutide 2.4 mg. Participants had lost a mean of 17.3% of body weight over 68 weeks on the drug. After withdrawal, they regained about two-thirds of that lost weight, ending at a net loss of roughly 5.6% from baseline by week 120 (STEP-1 extension, Diabetes Obes Metab 2022). The cardiometabolic improvements — blood pressure, lipids, blood sugar — also drifted back toward where they started.

SURMOUNT-4 showed the same pattern with tirzepatide, and even more starkly. After a 36-week lead-in on tirzepatide, participants were randomized to either continue the drug or switch to placebo for 52 more weeks. The continued-tirzepatide group had an additional 5.5% weight loss over that period. The placebo (withdrawal) group gained 14.0% (SURMOUNT-4, JAMA 2024). That's a ~20 percentage-point swing between staying on and coming off.

Why the weight comes back

The regain isn't a willpower failure. GLP-1 medications lower appetite partly by acting on hunger and satiety signaling. When the drug leaves your system, appetite drivers return, and the body's tendency to defend a higher weight set-point reasserts itself. The medication was doing real physiological work; remove it, and that work stops.

There's a useful detail buried in the STEP-1 extension: even after regaining two-thirds of their loss, participants still ended up net below baseline (−5.6% at week 120). So stopping doesn't erase everything. But a 5.6% net loss is a fraction of the 17.3% these same people held while on the drug. The gap between those two numbers is the price of stopping — and it's the exact gap a maintenance strategy is trying to close.

This is why the "just take it until you're thin, then quit" plan fails for most people, and why the maintenance question exists at all. The scale doesn't stay where you left it.

Trial	Drug	On-drug result	After withdrawal
STEP-1 extension (2022)	Semaglutide 2.4 mg	−17.3% at wk 68	Regained ~2/3; net −5.6% at wk 120
SURMOUNT-4 (2024)	Tirzepatide 10–15 mg	Continued −5.5% (wk 36→88)	Placebo group +14.0%
STEP-4 (2021)	Semaglutide 2.4 mg	Continued to −17.4% total	Placebo group regained steadily

Does Continued Treatment Actually Work?

Yes — this is the part with strong evidence.

STEP-4 was built to answer it directly. After a 20-week run-in on semaglutide 2.4 mg, participants were randomized to either continue the drug or switch to placebo. Those who continued kept losing, reaching an estimated 17.4% total reduction. Those who switched to placebo regained weight steadily (STEP-4, JAMA 2021). Staying on the drug clearly beat stopping.

SURMOUNT-4 delivered the tirzepatide version of the same conclusion: 89.5% of people who continued tirzepatide maintained at least 80% of their lead-in weight loss, versus 16.6% on placebo (SURMOUNT-4, JAMA 2024).

So the evidence for continued full-dose treatment holding weight loss is robust. Both major drug classes, both large randomized trials, same answer: staying on works, stopping doesn't.

What these trials did not test is a reduced maintenance dose. In STEP-4 and SURMOUNT-4, the "continue" arm stayed at the high dose. Nobody was randomized to, say, 5 mg tirzepatide or 1.0 mg semaglutide as a maintenance step-down. That's the missing piece.

The honest gap in the evidence

Can a lower dose hold your loss? We genuinely don't have randomized trial data that says yes. It's biologically plausible that some people maintain on a smaller dose, and clinicians report it happening in practice. But "plausible and sometimes reported" is not the same as "proven in a trial." Anyone who tells you a specific step-down dose is guaranteed to hold your weight is going beyond the evidence.

The threshold dose that prevents regain appears to vary a lot person to person, and it can't be predicted from how you responded during titration. That's why any step-down is an experiment on you specifically, and why it needs monitoring.

Why the trials were built this way

It's worth understanding why these studies tested continuation versus withdrawal rather than a graded step-down. The maintenance trials — STEP-4 and SURMOUNT-4 — used a "randomized withdrawal" design. Everyone takes the active drug during an open-label lead-in until they've lost weight, then the group splits: half keep the drug, half switch to placebo. This design cleanly isolates one question: does the drug's ongoing presence matter? The answer, both times, was an emphatic yes.

But that design deliberately trades away nuance. It compares full dose against zero, because that's the cleanest test of whether the medication is doing the work. Testing a ladder of maintenance doses — 15 mg versus 10 mg versus 5 mg for people already at goal — would require a much larger, more expensive trial that nobody has run yet. So the evidence base is shaped like the trials that were feasible to run, not like the questions patients actually ask. Keep that in mind whenever someone quotes a maintenance dose with confidence.

How Dose Reduction Is Approached in Practice

Since there's no trial-defined maintenance dose, prescribers who attempt a step-down generally borrow principles from how these drugs are titrated up — go slow, watch the scale, and be ready to reverse.

A cautious approach looks like this:

Reach and stabilize. Confirm your weight has been stable at goal for a meaningful stretch (often a few months), not just touched the number once.
Change one step at a time. Move down a single dose level, not several — e.g., tirzepatide 15 mg to 12.5 mg, not straight to 5 mg.
Hold and observe. Stay at the new dose for several weeks to a couple of months and track weight, appetite, and how you feel.
React to the trend. If weight stays stable, you may consider another small step down later. If it starts climbing, that's your signal the lower dose isn't enough — step back up.

This mirrors the logic behind slow titration on the way up, where randomized and pooled data show that following labeled dose-escalation schedules reduces nausea and discontinuation compared with rushing. The same "slow and monitored" principle applies in reverse.

For the mechanics of titrating up in the first place, see our semaglutide dosing schedule guide. If a lower dose brings back nausea as your body re-adjusts, our tips for managing tirzepatide nausea still apply.

Approved doses you'd be stepping between

Drug	Approved maintenance doses (weight management)	Notes
Semaglutide (Wegovy)	1.7 mg or 2.4 mg weekly	2.4 mg is the target maintenance dose per label
Tirzepatide (Zepbound)	5, 10, or 15 mg weekly	Any of these can be a maintenance dose per label
Semaglutide (Ozempic, off-label for weight)	Up to 2.0 mg weekly	Approved for type 2 diabetes

Doses and indications reflect FDA-approved labeling (Wegovy label 2024; Zepbound label 2026; Ozempic label 2025). Zepbound's label explicitly lists 5, 10, and 15 mg as maintenance options, which gives more built-in flexibility to step down than Wegovy's single 2.4 mg target.

What About the Lower-Dose Data We Do Have?

We're not completely in the dark. A few trials give indirect hints.

STEP-8 compared weekly semaglutide 2.4 mg against daily liraglutide 3.0 mg (an older, weaker GLP-1) and placebo. Semaglutide produced about −15.8% versus −6.4% with liraglutide (STEP-8, JAMA 2022). That's a comparison of different drugs, not a step-down of the same drug — but it confirms that a less potent GLP-1 regimen produces meaningfully less weight effect. It's a caution against assuming "any GLP-1 at any dose" holds the line equally.

The dose-ranging data from the pivotal efficacy trials also matters. In SURMOUNT-1, tirzepatide produced roughly −15% at 5 mg, −19.5% at 10 mg, and −20.9% at 15 mg over 72 weeks (SURMOUNT-1, NEJM 2022). The dose-response is real: lower doses did less. That doesn't prove a lower dose can't maintain an already-achieved loss — maintaining and achieving are different tasks — but it should temper the assumption that dropping to 5 mg is consequence-free.

The head-to-head data reinforces how much potency drives results. In SURMOUNT-5, the first direct comparison of the two drugs, tirzepatide reached −20.2% versus −13.7% for semaglutide at 72 weeks (SURMOUNT-5, NEJM 2025). A more potent agent produced more loss. The through-line across all of this data is consistent: with GLP-1s, dose and potency track with effect on the way up.

Put simply: the drugs work in a dose-dependent way going up. Whether that dose-dependence flips off once you're already at goal is the open question — and it's the single most important unanswered question in GLP-1 maintenance.

Trial	Comparison	Key result	What it tells us about dose
SURMOUNT-1 (2022)	Tirzepatide 5 vs 10 vs 15 mg	−15% / −19.5% / −20.9%	Clear dose-response going up
SURMOUNT-5 (2025)	Tirzepatide vs semaglutide	−20.2% vs −13.7%	More potent agent, more loss
STEP-8 (2022)	Semaglutide vs liraglutide	−15.8% vs −6.4%	Weaker GLP-1, weaker effect

Cost, Side Effects, and Why People Want to Step Down

The motivation to reduce is real and reasonable.

Cost. List prices for brand GLP-1s run over $1,000/month without coverage, and self-pay is common because insurance often won't cover these drugs for weight loss. A lower dose can sometimes mean a cheaper vial or stretching supply — though pen and vial pricing doesn't always scale neatly with dose. For a full breakdown, see our GLP-1 cost and access guide.

Side effects. Nausea, constipation, and other GI effects are dose-related for many people. A smaller maintenance dose may ease them.

Just wanting less medication. Understandable, and legitimate — but weigh it against the regain risk the trials documented.

There's a subtlety on cost worth flagging. Because Zepbound's label lists 5, 10, and 15 mg as valid maintenance doses, a step-down there stays fully on-label. Wegovy's maintenance target is a single dose (2.4 mg, or 1.7 mg if 2.4 isn't tolerated), so a deeper reduction moves you below the labeled maintenance dose — which is a different conversation with your prescriber than staying within approved options. That labeling difference is one reason tirzepatide users have more built-in room to experiment with a lower maintenance dose.

The tension is straightforward: the trials prove full-dose continuation holds weight; your wallet and your gut may prefer less. There's no free lunch, and the "right" answer depends on your goals, your regain risk, and what your prescriber sees in your data.

If you and your clinician decide a full stop is the goal (not just a step-down), our guides on stopping semaglutide and the Zepbound stopping protocol cover how to reduce regain risk when coming off entirely.

Protecting Your Results at Any Dose

Whatever dose you land on, the non-drug pieces get more important, not less — especially muscle.

Rapid weight loss on GLP-1s includes some lean mass, and lean mass is metabolically active tissue you want to keep. Prioritizing protein intake and resistance training is the evidence-informed way to protect it. Our muscle-loss prevention protocol covers the specifics.

If your weight stalls before you even reach goal — a different problem from maintenance — our GLP-1 plateau guide walks through the likely causes and what actually helps.

None of these habits replace the medication's biological effect. They complement it, and they're what stands between you and the trajectory the placebo arms took.

How to Monitor a Step-Down (and When to Reverse It)

If you and your clinician decide to try a lower maintenance dose, monitoring is what turns a gamble into a controlled test. The trials give you the numbers that define "working" versus "not working."

Use a consistent measurement. Weigh yourself the same way — same time of day, same conditions, ideally weekly — so you're tracking a trend, not daily water-weight noise. A single higher reading is nothing. A steady upward drift over several weeks is signal.

Set a threshold in advance. Because SURMOUNT-4 showed that people who maintained held roughly 80% or more of their loss, a reasonable personal rule is to define how much regain you'll tolerate before stepping back up. Some clinicians use a few pounds, or a small percentage of body weight, as the trigger. Deciding the number before you start removes the temptation to rationalize a creeping trend.

Watch more than the scale. Returning hunger, bigger portions, or fading fullness between meals often precede the weight itself. Those are early warning signs the lower dose isn't covering you.

Red flags that mean "reassess with your prescriber"

Steady weight gain over 4–8 weeks after a dose reduction
Appetite and food preoccupation clearly returning to pre-treatment levels
Regaining more than the amount you and your clinician agreed was acceptable
Any new or worsening symptoms after a dose change

Reversing a step-down is not a failure — it's the system working. The whole point of changing one dose level at a time is that you can climb back up if the data tells you to. The people in SURMOUNT-4's continuation arm didn't hold their weight by luck; they held it because they stayed on an effective dose. If your lower dose isn't effective for you, the honest response is to go back to one that is.

Who Might Reasonably Try a Lower Dose?

There's no evidence-defined "good candidate" for stepping down, because the step-down itself hasn't been formally trialed. But some situations make a supervised attempt more sensible than others.

A supervised trial may make sense if:

Your weight has been genuinely stable at goal for several months, not days
You're motivated primarily by dose-related side effects or cost, not by wanting to quit
You have a prescriber who will monitor you and adjust the dose based on data
You're committed to the protein-and-resistance-training foundation regardless of dose

More caution is warranted if:

You have a long history of weight cycling or rapid regain after past diet attempts
Your goal weight was only recently reached and hasn't stabilized
You'd be reducing the dose without any structured follow-up
Significant health conditions were driving the decision to lose weight in the first place

This isn't a scorecard, and none of it substitutes for a clinician's judgment about your specific case. See our candidate eligibility guide for the broader question of who these drugs suit in the first place. The point here is narrower: a step-down is lower-risk when you're stable, monitored, and ready to reverse — and higher-risk when you're not.

Frequently Asked Questions

Is there an official "maintenance dose" for GLP-1s? For weight management, the FDA-approved maintenance dose of Wegovy is 2.4 mg weekly (or 1.7 mg if 2.4 isn't tolerated). Zepbound lists 5, 10, or 15 mg as maintenance options. There is no separate, lower "maintenance-only" dose that trials proved will hold your loss.

Can I cut my dose in half once I reach my goal weight? Some people do reduce their dose with clinician guidance, but no randomized trial has shown a specific reduced dose reliably prevents regain. If you try it, do it gradually and with monitoring, and be prepared to step back up if weight climbs. This is a decision for you and your prescriber, not a DIY move.

How much weight will I regain if I stop completely? In the STEP-1 extension, people regained about two-thirds of their lost weight roughly a year after stopping semaglutide (Diabetes Obes Metab 2022). Individual results vary, but substantial regain after full withdrawal is the common pattern in the trials.

Do I have to take a GLP-1 forever? Obesity is treated as a chronic condition, and the trial evidence shows weight tends to return when the drug is stopped. Many people take these medications long-term. Whether that's right for you depends on your health goals and your clinician's assessment — there's no one-size answer.

Does a lower dose have fewer side effects? Often, yes — many GI side effects are dose-related, so a smaller dose may be gentler. The trade-off is the uncertain effect on weight maintenance. That's the balance to discuss with your prescriber.

The Bottom Line

The trials are clear on one thing: staying on a GLP-1 holds your weight loss, and stopping brings most of it back. What they haven't settled is whether a lower "maintenance dose" can do the same job with fewer side effects and lower cost. That's an open question, not a solved one.

If you're thinking about stepping down, treat it as a supervised experiment: change one dose level at a time, watch the scale, and be ready to reverse. Keep the protein and resistance training high regardless of dose. And make the call with a prescriber who's looking at your actual data — not a marketing page promising a magic maintenance number the evidence doesn't support.

Sources

Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022 Aug. PMID: 35441470. https://pubmed.ncbi.nlm.nih.gov/35441470/
Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024 Jan 2. PMID: 38078870. https://pubmed.ncbi.nlm.nih.gov/38078870/
Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021 Apr 13. PMID: 33755728. https://pubmed.ncbi.nlm.nih.gov/33755728/
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021 Mar 18. PMID: 33567185. https://pubmed.ncbi.nlm.nih.gov/33567185/
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022 Jul 21. PMID: 35658024. https://pubmed.ncbi.nlm.nih.gov/35658024/
Rubino DM, et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (STEP 8). JAMA. 2022 Jan 11. PMID: 35015037. https://pubmed.ncbi.nlm.nih.gov/35015037/
Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025 Jul 3. PMID: 40353578. https://pubmed.ncbi.nlm.nih.gov/40353578/
FDA Prescribing Information — Wegovy (semaglutide) injection, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
FDA Prescribing Information — Zepbound (tirzepatide) injection, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s002lbl.pdf
FDA Prescribing Information — Ozempic (semaglutide) injection, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf

— The GLP-1 Daily Team

GLP-1 Maintenance Dose: The Lowest Effective Dose After Goal Weight [2026]